-
公开(公告)号：US07214799B2
公开(公告)日：2007-05-08
申请号：US11054527
申请日：2005-02-09
申请人： Raja Khalifah , Roland Keilitz , Christoph Koellner , Thorsten Degenhardt , Stephen Robert Brand
发明人： Raja Khalifah , Roland Keilitz , Christoph Koellner , Thorsten Degenhardt , Stephen Robert Brand
IPC分类号： C07D213/62
CPC分类号： C07D213/66 , C07D213/67 , C07D401/06 , C07D401/12
摘要： The invention provides non-oxidative methods for the large scale manufacture of pyridoxamine (I) (4-aminomethyl-3-hydroxy-5-hydroxymethyl-2-methylpyridine): and salts thereof. The invention also provides intermediate compounds for the synthesis of pyridoxamine, as well as compositions and methods for the treatment and/or prevention of conditions associated with the formation of post-Amadori advanced glycation end-products.
摘要翻译： 本发明提供了用于大规模生产吡哆胺（I）（4-氨基甲基-3-羟基-5-羟甲基-2-甲基吡啶）的非氧化方法及其盐。 本发明还提供了用于合成吡哆胺的中间体化合物，以及用于治疗和/或预防与后阿马多后期糖基化终产物形成相关的病症的组合物和方法。
-
公开(公告)号：US20100305162A1
公开(公告)日：2010-12-02
申请号：US12855108
申请日：2010-08-12
申请人： Raja Khalifah , Roland Keilitz , Christoph Koellner , Thorsten Degenhardt , Stephen Robert Brand
发明人： Raja Khalifah , Roland Keilitz , Christoph Koellner , Thorsten Degenhardt , Stephen Robert Brand
IPC分类号： A61K31/444 , C07D213/66 , A61K31/44 , A61P3/10 , A61P3/06 , A61P13/12 , A61P25/00 , A61P27/02 , A61P9/10
CPC分类号： C07D213/66 , C07D213/67 , C07D401/06 , C07D401/12
摘要： The invention provides non-oxidative methods for the large scale manufacture of pyridoxamine (I) (4-aminomethyl-3-hydroxy-5-hydroxymethyl-2-methylpyridine): and salts thereof. The invention also provides intermediate compounds for the synthesis of pyridoxamine, as well as compositions and methods for the treatment and/or prevention of conditions associated with the formation of post-Amadori advanced glycation end-products.
摘要翻译： 本发明提供了用于大规模生产吡哆胺（I）（4-氨基甲基-3-羟基-5-羟甲基-2-甲基吡啶）的非氧化方法及其盐。 本发明还提供了用于合成吡哆胺的中间体化合物，以及用于治疗和/或预防与后阿马多后期糖基化终产物形成相关的病症的组合物和方法。
-
公开(公告)号：US20050272781A1
公开(公告)日：2005-12-08
申请号：US11054527
申请日：2005-02-09
IPC分类号： A61K31/4415 , C07D213/62 , C07D213/66 , C07D213/67 , C07D401/12
CPC分类号： C07D213/66 , C07D213/67 , C07D401/06 , C07D401/12
摘要： The invention provides non-oxidative methods for the large scale manufacture of pyridoxamine (I) (4-aminomethyl-3-hydroxy-5-hydroxymethyl-2-methylpyridine): The invention also provides intermediate compounds for the synthesis of pyridoxamine, as well as compositions and methods for the treatment and/or prevention of conditions associated with the formation of post-Amadori advanced glycation end-products.
摘要翻译： 本发明提供用于大规模生产吡哆胺（I）（4-氨基甲基-3-羟基-5-羟甲基-2-甲基吡啶）的非氧化方法：本发明还提供用于合成吡哆胺的中间体化合物，以及 用于治疗和/或预防与后阿马多后期糖基化终产物形成相关的病症的组合物和方法。
-
公开(公告)号：US20070161678A1
公开(公告)日：2007-07-12
申请号：US11725094
申请日：2007-03-16
IPC分类号： A61K31/444 , A61K31/4415 , C07D211/72
CPC分类号： C07D213/66 , C07D213/67 , C07D401/06 , C07D401/12
摘要： The invention provides non-oxidative methods for the large scale manufacture of pyridoxamine (I) (4-aminomethyl-3-hydroxy-5-hydroxymethyl-2-methylpyridine): (I), and salts thereof. The invention also provides intermediate compounds for the synthesis of pyridoxamine, as well as compositions and methods for the treatment and/or prevention of conditions associated with the formation of post-Amadori advanced glycation end-products.
摘要翻译： 本发明提供了用于大规模生产吡哆胺（I）（4-氨基甲基-3-羟基-5-羟甲基-2-甲基吡啶）：（I）的非氧化方法及其盐。 本发明还提供了用于合成吡哆胺的中间体化合物，以及用于治疗和/或预防与后阿马多后期糖基化终产物形成相关的病症的组合物和方法。
-
公开(公告)号：US08431712B2
公开(公告)日：2013-04-30
申请号：US12855108
申请日：2010-08-12
申请人： Raja G. Khalifah , Roland Keilitz , Christoph Koellner , Thorsten Degenhardt , Stephen Robert Brand
发明人： Raja G. Khalifah , Roland Keilitz , Christoph Koellner , Thorsten Degenhardt , Stephen Robert Brand
IPC分类号： C07D213/62
CPC分类号： C07D213/66 , C07D213/67 , C07D401/06 , C07D401/12
摘要： The invention provides non-oxidative methods for the large scale manufacture of pyridoxamine (I) (4-aminomethyl-3-hydroxy-5-hydroxymethyl-2-methylpyridine): and salts thereof. The invention also provides intermediate compounds for the synthesis of pyridoxamine, as well as compositions and methods for the treatment and/or prevention of conditions associated with the formation of post-Amadori advanced glycation end-products.
摘要翻译： 本发明提供了用于大规模生产吡哆胺（I）（4-氨基甲基-3-羟基-5-羟甲基-2-甲基吡啶）的非氧化方法及其盐。 本发明还提供了用于合成吡哆胺的中间体化合物，以及用于治疗和/或预防与后阿马多后期糖基化终产物形成相关的病症的组合物和方法。
-
公开(公告)号：US20090082407A1
公开(公告)日：2009-03-26
申请号：US12325818
申请日：2008-12-01
IPC分类号： A61K31/44
CPC分类号： A61K31/44 , A61K31/4412 , A61K45/06
摘要： The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient.
摘要翻译： 本发明提供药物组合物，其包含吡哆胺的剂量单位或其药学上可接受的盐; 和药学上可接受的载体，及其用于限制人类糖尿病患者中肾病和/或糖尿病并发症进展的方法。
-
公开(公告)号：US20130011379A1
公开(公告)日：2013-01-10
申请号：US13446442
申请日：2012-04-13
CPC分类号： A61K31/44 , A61K31/4412 , A61K45/06
摘要： The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient.
-
公开(公告)号：US20050014799A1
公开(公告)日：2005-01-20
申请号：US10871224
申请日：2004-06-18
IPC分类号： A61K31/44 , A61K31/4412 , A61K45/06 , A61P3/10 , A61P13/00
CPC分类号： A61K45/06 , A61K31/44 , A61K31/4412 , A61K2300/00
摘要： The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient.
摘要翻译： 本发明提供药物组合物，其包含吡哆胺的剂量单位或其药学上可接受的盐; 和药学上可接受的载体，及其用于限制人类糖尿病患者中肾病和/或糖尿病并发症进展的方法。
-
公开(公告)号：US20110178139A1
公开(公告)日：2011-07-21
申请号：US13077002
申请日：2011-03-31
CPC分类号： A61K31/44 , A61K31/4412 , A61K45/06
摘要： The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient.
摘要翻译： 本发明提供药物组合物，其包含吡哆胺的剂量单位或其药学上可接受的盐; 和药学上可接受的载体，及其用于限制人类糖尿病患者中肾病和/或糖尿病并发症进展的方法。
-
10.发明申请Pyridoxamine for the Treatment of Diabetic Intermediaries and Post-Amadori Inhibition 有权吡哆胺用于治疗糖尿病中介和后阿马多利抑制公开(公告)号：US20080119525A1
公开(公告)日：2008-05-22
申请号：US12019819
申请日：2008-01-25
IPC分类号： A61K31/4412 , A61P3/10
CPC分类号： A61K45/06 , A61K31/44 , A61K31/4412 , A61K2300/00
摘要： The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient.
摘要翻译： 本发明提供药物组合物，其包含吡哆胺的剂量单位或其药学上可接受的盐; 和药学上可接受的载体，及其用于限制人类糖尿病患者中肾病和/或糖尿病并发症进展的方法。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.082 秒)
